Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBIS-2 study of darapladib in CHD
NCT00268996Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2005
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of darapladib in atherosclerosis and coronary heart disease (CHD) (4 arms), sponsored by GSK. Primary endpoints: Mean Circulating High Sensitivity C-Reactive Protein Levels at 52 weeks and Change From Baseline in the Density of Rotterdam Classification (ROC) Grade III/IV Strain Spots at 52 weeks. Started Nov 2005; status: completed.
02
Drugs
darapladib
03
Conditions
atherosclerosiscoronary heart disease (CHD)
Beyond the preview
Go deeper on NCT00268996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268996.